CASE PA/4-33165A



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EVG78/1/3205/US

Express Mail Label Number

Date of Dec

JANUARY 9, 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

BOLLBUCK ET AL.

APPLICATION NO: 10/552,317

FILED: JULY 6, 2006

FOR: 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

LETTER CORRECTING OFFICIAL FILING RECEIPT

Sir:

The official filing receipt received in the above-identified application erroneously lists the "Applicant(s)" information. The country where the seventh inventor resides is incorrect. Enclosed is a copy of the Declaration which shows this to be true. Please issue a corrected filing receipt listing the Applicant(s) information as follows:

--Applicant(s)

Birgit Bollbuck, Weil am Rhein, GERMANY;

Alastair DenholMritain, West Sussex, UNITED KINGDOM;

Laszlo Revesz, Therwil, SWITZERLAND;

Achim Schlapbach, Lorrach, GERMANY;

Rudolf Walchli, Basel, SWITZERLAND;

Jorg Eder, Rheinfelden, GERMANY;

Rene Hersperger, Munchenstein, SWITZERLAND;

Philipp Janser, Basel, SWITZERLAND;

A copy of the filing receipt with the correction noted is enclosed.

No fee is believed to be required by this request for a corrected filing receipt.

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080

(862) 778-7951 Date: JANUARY 9, 2007 Respectfully submitted,

Peter J. Waibel

Attorney for Applicants

Reg. No. 43,228



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
PO. Box 1450
Alexandria, Viginia 22313-1450

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
	07/00/0000	4004	4700	544.004054		/40	

10/552,317

001095

NOVARTIS

07/06/2006

EAST HANOVER, NJ 07936-1080

1780

PA/4-33165A

CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3



CONFIRMATION NO. 2729 FILING RECEIPT *OC000000021329279*

Date Mailed: 11/24/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

- Birgit Bollbuck, Weil am Rhein, GERMANY;
- ✓Alastair DenholMritain, West Sussex, UNITED KINGDOM;
- Laszlo Revesz, Therwil, SWITZERLAND;
- ~Achim Schlapbach, Lorrach, GERMANY;
- ✓Rudolf Walchli, Basel, SWITZERLAND;
- ✓Jorg Eder, Rheinfelden, GERMANY;
- Rene Hersperger, Munchenstein, GERMANY; SwitzeRIAnd,
- Philipp Janser, Basel, SWITZERLAND;

Power of Attorney: The patent practitioners associated with Customer Number 001095.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP04/03819 04/08/2004

Foreign Applications

WINITED KINGDOM 0308466.2 04/11/2003

If Required, Foreign Filing License Granted: 11/22/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/552,317**

Projected Publication Date: 03/01/2007



Non-Publication Request: No

Early Publication Request: No

Title

2-Aminopyrimidine derivatives and their medical use

Preliminary Class

544

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where

the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

US Case PA

ECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION

×	Original		Supplemental		Substitute			
As a	below named inventor, I here	by de	eclare that:					
Му	residence, post office address	and (citizenship are as stated below next to	my i	name, and			
and	I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled							
2-A	2-AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE							
the :	specification of which:							
	is attached hereto.							
	was filed on (day	/mor	as Application No					
	and, if this box (\square) contain	s an	×					
	☐ was amended on	(da	y/month/year)					
X	·	atior	Treaty international Application No.					
	PCT/EP 2004/003819 on 08/04/2004 (day/month/year)							
	and, if this box (\square) contain	s an	×					
	entered the national	al sta	ge in the United States and was accor	ded	Application No.			
	and, if this box (□) contain	s an	*					
	was amended, sub	sequ	ent to entry into the national stage, on	_	(day/month/year)			

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) specifically referred to above and, if this application was filed as a Patent Cooperation Treaty international application, by any amendments made during the international stage (including any made under Patent Cooperation Treaty Rule 91, Article 19 and Article 34).

I acknowledge my duty to disclose information which is material to patentability as defined in 37 C.F.R. 1.56, including, for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or Patent Cooperation Treaty international filing date of the continuation-in-part application.

I hereby claim the benefit under 35 U.S.C. 119(a)-(d) or (f) or 365(b) of any foreign application(s) for patent, inventor's certificate or plant breeder's right certificate listed below and under 35 U.S.C. 365(a) of any Patent Cooperation Treaty international application(s) designating at least one country other than the United States listed below and have also listed below any foreign application(s) for patent, inventor's certificate or plant breeder's right certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application the priority of which is claimed for that subject matter:

COUNTRY/REGION (OR P.C.T.)	APPLICATION No.	FILING DATE (day/month/year)	Р	RIORIT	Y CLA	IMED	
GB	0308466.2	11/04/2003	×	Yes		No	
0D	•			Yes		No	
				Yes		No	
				Yes		No	
		•		Yes		No	
I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below:							
APPLICATION NO.		FILING DATE (day/month/year)					

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s) listed below and under 35 U.S.C. 365(c) of any Patent Cooperation Treaty international application(s) designating the United States listed below:

United States	United States	Status (Pending,	International		
Application No.	Filing Date	Abandoned or U.S.	Application No.	and Filing Date	
	(day/month/year)	Patent No.)		(day/month/year)	

I hereby appoint all of the registered practitioners associated with Customer No. 001095, respectively and individually, as my attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

If this box (\square) contains an x \boxtimes , I hereby authorize the registered practitioners associated with Customer No. 001095 and any others acting on my behalf to take any action relating to this application based on communications from Corporate Intellectual Property of Novartis International AG, Basle, Switzerland, or an affiliate thereof or a successor thereto, without direct communication from me.

Please send all correspondence relating to this application to the address associated with Customer No. 001095.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole or first joint inventor	Birgit BOLLBUCK		
Inventor's signature	Zirgit Bollbruk	Date -	29 / 09 / 05 (day/month/year)
Residence	79576 Weil am Rhein, Germany		
Citizenship	Germany		
Post Office Address	Bodenseestrasse 23, 79576 Weil am Rhein, Germany		
Full name of second joint inventor, if any	Alastair DENHOLMritain		
Inventor's signature		Date	
			(day/month/year)
Residence	Horsham, West Sussex RH12 5AB, Great Britain		
Citizenship	Great Britain		
Post Office Address	Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB, Great Britain		

IMPORTANT: Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

Full name of third joint inventor, if any	Jörg EDER		
Inventor's signature	S. S	Date _	(day/month/year)
Residence	79618 Rheinfelden, Germany		
Citizenship	Germany		
Post Office Address	Zwischen den Bächen 4, 79618 Rheinfelden, Germany		
Full name of fourth joint inventor, if any	René HERSPERGER		
Inventor's signature	Pour 1 kingeyls	Date	30 /03 / 200 (day/month/year)
Residence	4142 Münchenstein, Switzerland		
Citizenship	Switzerland		
Post Office Address	Höhenweg 32, 4142 Münchenstein, Switzerland		
Full name of fifth joint inventor, if any	Philipp JANSER		
Inventor's signature	Philipp Janses	Date	30/09/2005 (day/month/year)
Residence	4053 Basel, Switzerland		
Citizenship	Switzerland		
Post Office Address	Delsbergerallee 1, 4053 Basel, Switzerland		

Full name of sixth joint inventor, if any	Lászlo RÉVÉSZ		
Inventor's signature	Linko Révén	Date	4 / 10 / 05 (day/month/year)
Residence	4106 Therwil, Switzerland		
Citizenship	Switzerland		
Post Office Address	Ob dem Fichtenrain 7, 4106 Therwil, Switzerland		
Full name of seventh joint inventor, if any	Achim SCHLAPBACH		
Inventor's signature	10 - 1209	Date .	29 /09 /0 5 (day/month/year)
Residence	79539 Lörrach, Germany		
Citizenship	Germany		
Post Office Address	Hünerbergweg 8, 79539 Lörrach, Germany		
Full name of eighth joint inventor, if any	Rudolf WÄLCHLI		
Inventor's signature	Andolf Ralchli	Date -	30 /09/05 (day/month/year)
Residence	4056 Basel, Switzerland		
Citizenship	Switzerland		
Post Office Address	St. Johanns-Vorstadt 90, 4056 Basel, Switzerland		



DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION

×	Original			Supplemental		Substitute
As a	below nan	ned inventor, I her	eby de	eclare that:		
My r	esidence, p	ost office address	s and	citizenship are as stated below next to	my r	name, and
and	joint invent	or (if more than or	ne nar	le inventor (if only one name is listed ne is listed below) of the subject matte on the invention entitled		
2-Ai	MINOPYRI	MIDINE DERIVAT	IVES	AND THEIR MEDICAL USE		
the s	specification	of which:				
	is attach	ed hereto.		•		
	was filed		sy/mon	as Application No		
	and, if th	nis box (□) contai	ns an	×		
		was amended on				
			(da	y/month/year)		
×		·	ration	Treaty international Application No.		
	PCT/EP	2004/003819		on 08/04/2004 (day/month/year)		
	and, if th	is box (□) contair	ns an	×		
		entered the nation	al sta	ge in the United States and was accor	ded .	Application No.
	and, if th	is box (□) contair	ns an	<u>*</u>		
		vas amended, sut	osegu	ent to entry into the national stage, on	1	
		·	•	,		(day/month/year)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) specifically referred to above and, if this application was filed as a Patent Cooperation Treaty international application, by any amendments made during the international stage (including any made under Patent Cooperation Treaty Rule 91, Article 19 and Article 34).

I acknowledge my duty to disclose information which is material to patentability as defined in 37 C.F.R. 1.56, including, for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or Patent Cooperation Treaty international filing date of the continuation-in-part application.

I hereby claim the benefit under 35 U.S.C. 119(a)-(d) or (f) or 365(b) of any foreign application(s) for patent, inventor's certificate or plant breeder's right certificate listed below and under 35 U.S.C. 365(a) of any Patent Cooperation Treaty international application(s) designating at least one country other than the United States listed below and have also listed below any foreign application(s) for patent, inventor's certificate or plant breeder's right certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application the priority of which is claimed for that subject

COUNTRY/REGION (OR P.C.T.)				PRIORITY CLAIMED				
GB	0308466.2	11/04/2003	×	Yes		No		
GB				Yes		No		
				Yes		No		
				Yes		No		
				Yes		No		
I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below:								
APPLICATION NO.		FILING DATE (day/month/year)						

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s) listed below and under 35 U.S.C. 365(c) of any Patent Cooperation Treaty international application(s) designating the United States listed below:

	United States Application No.	United States Filing Date (day/month/year)	Status (Pending, Abandoned or U.S. Patent No.)	Interna Application No.	ational and Filing Date (day/month/year)
--	-------------------------------	--	--	----------------------------	--

I hereby appoint all of the registered practitioners associated with Customer No. 001095, respectively and individually, as my attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

If this box (□) contains an x ☒, I hereby authorize the registered practitioners associated with Customer No. 001095 and any others acting on my behalf to take any action relating to this application based on communications from Corporate Intellectual Property of Novartis International AG, Basle, Switzerland, or an affiliate thereof or a successor thereto, without direct communication from me.

Please send all correspondence relating to this application to the address associated with Customer No. 001095.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole or first joint inventor	Birgit BOLLBUCK		
Inventor's signature		Date	(day/month/year)
Residence	79576 Weil am Rhein, Germany		
Citizenship	Germany Bodenseestrasse 23, 79576 Weil am		
Post Office Address	Rhein, Germany		
Full name of second joint inventor, if any	Alastair DENHOLM		
Inventor's signature	ADanin	Date .	14/11/W05 (day/month/year)
Residence	Horsham, West Sussex RH12 5AB, Great Britain		
Citizenship	Great Britain		
Post Office Address	Novartis Pharmaceuticals UK Ltd, Patents and Trademarks, Wimblehurst Road, Horsham, West Sussex RH12 5AB, Great Britain		

IMPORTANT: Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

Full name of third joint inventor, if any	Jörg EDER		
Inventor's signature		Date -	
			(day/month/year)
Residence	79618 Rheinfelden, Germany		
Citizenship	Germany		
Post Office Address	Zwischen den Bächen 4, 79618 Rheinfelden, Germany		
Full name of fourth joint inventor, if any	René HERSPERGER		
Inventor's signature		Date	
			(day/month/year)
Residence	4142 Münchenstein, Switzerland		
Citizenship	Switzerland		
Post Office Address	Höhenweg 32, 4142 Münchenstein, Switzerland		
Full name of fifth joint inventor, if any	Philipp JANSER		
Inventor's signature		Date	
		-	(day/month/year)
Residence	4053 Basel, Switzerland		
Citizenship	Switzerland		
Post Office Address	Delsbergerallee 1, 4053 Basel, Switzerland		

Full name of sixth joint inventor, if any	Lászlo RÉVÉSZ		
Inventor's signature		Date	
			(day/month/year)
Residence	4106 Therwil, Switzerland		
Citizenship	Switzerland		
Post Office Address	Ob dem Fichtenrain 7, 4106 Therwil, Switzerland		
Full name of seventh joint inventor, if any	Achim SCHLAPBACH		
Inventor's signature		Date	
			(day/month/year)
Residence	79539 Lörrach, Germany		
Citizenship	Germany		
Post Office Address	Hünerbergweg 8, 79539 Lörrach, Germany		
Full name of eighth joint inventor, if any	Rudolf WÄLCHLI		
Inventor's signature		Date _	
			(day/month/year)
Residence	4056 Basel, Switzerland		
Citizenship	Switzerland		
Post Office Address	St. Johanns-Vorstadt 90, 4056 Basel, Switzerland		